2020
Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort.
Erickson B, Najjar O, Klein M, Shahi M, Dolan M, Cimino-Mathews A, Grandelis A, Buza N, Delaney P, Tymon-Rosario J, Santin A, Ferriss J, Stone R, Nickles Fader A. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort. Journal Of Clinical Oncology 2020, 38: 6084-6084. DOI: 10.1200/jco.2020.38.15_suppl.6084.Peer-Reviewed Original ResearchHuman epidermal growth factor 2Uterine serous carcinomaEarly stage uterine serous carcinomaEarly-stage diseaseMulti-institutional cohortHER2-positive tumorsSerous carcinomaOverall survivalHER2 overexpressionStage ILymph-vascular space invasionHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Epidermal growth factor 2Endometrial cancer deathsHER2-positive cohortHER2-positive diseaseStage IB diseaseBreast cancer guidelinesGrowth factor receptor 2HER2-negative tumorsWorse survival outcomesKaplan-Meier analysisBody mass indexPoor prognostic tumor
2014
HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges
Buza N, Roque DM, Santin AD. HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges. Archives Of Pathology & Laboratory Medicine 2014, 138: 343-50. PMID: 24576030, DOI: 10.5858/arpa.2012-0416-ra.Peer-Reviewed Original ResearchConceptsEndometrial carcinomaHER2/neuPromising therapeutic targetHER2 testingClinical responseTherapeutic targetHumanized monoclonal immunoglobulin G1 antibodyMonoclonal immunoglobulin G1 antibodyUterine serous carcinomaImmunoglobulin G1 antibodyNovel therapeutic strategiesEndometrial cancerSerous adenocarcinomaSerous carcinomaCase reportDiagnostic challengeHER2 overexpressionPathogenetic featuresClinical studiesG1 antibodyTherapeutic strategiesCarcinomaTherapeutic efficacyStandardized criteriaTherapy
2013
Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice
Buza N, English DP, Santin AD, Hui P. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Modern Pathology 2013, 26: 1605-1612. PMID: 23765245, DOI: 10.1038/modpathol.2013.113.Peer-Reviewed Original ResearchConceptsEndometrial serous carcinomaSerous carcinomaHER2 overexpressionEndometrial carcinomaMedical recordsImmunohistochemical scoreHER2 testingProtein expressionHER2 immunohistochemistrySignificant heterogeneityScoring systemMultiple tumor sectionsPure serous carcinomaHER2-positive casesHER2-positive tumorsScoring criteriaEndometrial carcinoma casesFDA criteriaPatients' medical recordsLarge academic centerHER2 FISH resultsHER2 protein overexpressionPromising therapeutic targetOverall concordance rateHER2 immunohistochemical scores